The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The use of hybrid hybridomas to target human cytotoxic T lymphocytes
Abstract
This study describes a general strategy to produce hybrid monoclonal antibodies that are capable of targeting human cytotoxic T lymphocytes (CTL) against any cell carrying the appropriate target antigen. This is done by fusing a HAT‐sensitive, G418‐resistant anti‐T3 hybridoma with immune spleen cells (or with other hybridomas) that produce antibodies against the desired target antigen. In the hybrid hybridomas the reassortment of Ig heavy and light chains results in the production of bifunctional antibody molecules. Because of their double specificity, these antibodies are able to bridge human CTL to target cells and trigger cytotoxic function. We have isolated several stable hybrid hybridomas in which one specificity is against T3 and one either against HLA antigens (class II, DC‐1, A3), human Ig (IgM, IgE, x), Toxoplasma gondii or an ovary carcinoma‐associated antigen. In all of these cases we show that culture supernatants can efficiently and specifically target any CTL clone against any target cell that possesses the relevant surface antigen recognized by the antibody. Furthermore, the killing requires as little as 0.1 ng/ml of antibody, occurs at effector to target ratios comparable to those used in conventional cytotoxic assays and does not affect bystander cells. Nonspecific killing of Fc receptor‐positive cells can be avoided using F(ab′)2 fragments. As an example, we show that it is possible to (a) change the major histocompatibility complex class and allospecificity of a CTL clone and (b) target CTL against non‐major histocompatibility complex antigens such as Ig, parasites and tumor‐associated antigens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody
Perez, P., Hoffman, R. W., Shaw, S., Bluestone, J. A., & Segal, D. M. (1985) · Nature · doi:10.1038/316354a0 · Cited by 337
Cited by
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.031 · Cited by 1,775
Self-citationPenna, G., & Adorini, L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2405 · Cited by 1,267
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T., & Winter, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 874
Selective Expression of an Interleukin-12 Receptor Component by Human T Helper 1 Cells
Rogge, L., Barberis-Maino, L., Biffi, M., Passini, N., Presky, D. H., Gubler, U., & Sinigaglia, F. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.5.825 · Cited by 766
Valitutti, S., Dessing, M., Aktories, K., Gallati, H., & Lanzavecchia, A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.2.577 · Cited by 531
Self-citation
Metadata
- Authors
- Lanzavecchia, A., & Scheidegger, D.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 1987-01
- Volume
- 17
- Issue
- 1
- Pages
- 105-111
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2110544075
- Cited by
- 198
- References
- 1
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The use of hybrid hybridomas to target human cytotoxic T lymphocytes. https://app.cochat.ai/papers/10.1002/eji.1830170118
- The paper
- Lanzavecchia, A., & Scheidegger, D. (1987). The use of hybrid hybridomas to target human cytotoxic T lymphocytes. European Journal of Immunology. https://doi.org/10.1002/eji.1830170118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.